BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16165917)

  • 1. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
    Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
    Acta Oncol; 2005; 44(6):579-88. PubMed ID: 16165917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
    Ferrer L; Kraeber-Bodéré F; Bodet-Milin C; Rousseau C; Le Gouill S; Wegener WA; Goldenberg DM; Bardiès M
    Cancer; 2010 Feb; 116(4 Suppl):1093-100. PubMed ID: 20127958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
    J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
    Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
    J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
    Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.
    Siegel JA; Pawlyk DA; Lee RE; Sasso NL; Horowitz JA; Sharkey RM; Goldenberg DM
    Cancer Res; 1990 Feb; 50(3 Suppl):1039s-1042s. PubMed ID: 2297717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
    Breitz HB; Fisher DR; Wessels BW
    J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry.
    Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
    Cancer; 2002 Feb; 94(4 Suppl):1235-9. PubMed ID: 11877751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
    Shen S; Meredith RF; Duan J; Macey DJ; Khazaeli MB; Robert F; LoBuglio AF
    J Nucl Med; 2002 Sep; 43(9):1245-53. PubMed ID: 12215566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
    Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
    Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
    Kotzerke J; Glatting G; Seitz U; Rentschler M; Neumaier B; Bunjes D; Duncker C; Dohr D; Bergmann L; Reske SN
    J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.
    Wahl RL; Kroll S; Zasadny KR
    J Nucl Med; 1998 Aug; 39(8 Suppl):14S-20S. PubMed ID: 9708566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.
    Shen S; DeNardo GL; Sgouros G; O'Donnell RT; DeNardo SJ
    J Nucl Med; 1999 Dec; 40(12):2102-6. PubMed ID: 10616892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
    Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
    Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
    J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.
    Sgouros G
    J Nucl Med; 1993 Apr; 34(4):689-94. PubMed ID: 8455089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma.
    Du Y; Honeychurch J; Glennie M; Johnson P; Illidge T
    Cancer Res; 2007 Feb; 67(3):1335-43. PubMed ID: 17283171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
    Juweid M; Sharkey RM; Siegel JA; Behr T; Goldenberg DM
    Cancer Res; 1995 Dec; 55(23 Suppl):5827s-5831s. PubMed ID: 7493354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.